Aethlon Medical Statistics
Total Valuation
Aethlon Medical has a market cap or net worth of $4.32 million. The enterprise value is -$249,375.
| Market Cap | 4.32M |
| Enterprise Value | -249,375 |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aethlon Medical has 711,136 shares outstanding. The number of shares has increased by 497.17% in one year.
| Current Share Class | 711,136 |
| Shares Outstanding | 711,136 |
| Shares Change (YoY) | +497.17% |
| Shares Change (QoQ) | +52.56% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 9.78% |
| Float | 702,045 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.42 |
| Quick Ratio | 4.76 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -492.66 |
Financial Efficiency
Return on equity (ROE) is -160.91% and return on invested capital (ROIC) is -91.46%.
| Return on Equity (ROE) | -160.91% |
| Return on Assets (ROA) | -76.69% |
| Return on Invested Capital (ROIC) | -91.46% |
| Return on Capital Employed (ROCE) | -136.18% |
| Weighted Average Cost of Capital (WACC) | 10.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$770,836 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.33% in the last 52 weeks. The beta is 1.21, so Aethlon Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -83.33% |
| 50-Day Moving Average | 3.74 |
| 200-Day Moving Average | 8.40 |
| Relative Strength Index (RSI) | 63.75 |
| Average Volume (20 Days) | 4,863,231 |
Short Selling Information
The latest short interest is 74,846, so 10.52% of the outstanding shares have been sold short.
| Short Interest | 74,846 |
| Short Previous Month | 461,661 |
| Short % of Shares Out | 10.52% |
| Short % of Float | 10.66% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.08M |
| Pretax Income | -6.94M |
| Net Income | -6.94M |
| EBITDA | -6.77M |
| EBIT | -7.08M |
| Earnings Per Share (EPS) | -$31.45 |
Balance Sheet
The company has $4.93 million in cash and $367,608 in debt, with a net cash position of $4.57 million or $6.42 per share.
| Cash & Cash Equivalents | 4.93M |
| Total Debt | 367,608 |
| Net Cash | 4.57M |
| Net Cash Per Share | $6.42 |
| Equity (Book Value) | 5.20M |
| Book Value Per Share | 10.89 |
| Working Capital | 4.57M |
Cash Flow
In the last 12 months, operating cash flow was -$7.18 million and capital expenditures -$12,854, giving a free cash flow of -$7.19 million.
| Operating Cash Flow | -7.18M |
| Capital Expenditures | -12,854 |
| Depreciation & Amortization | 313,876 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.19M |
| FCF Per Share | -$10.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aethlon Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -497.17% |
| Shareholder Yield | -497.17% |
| Earnings Yield | -160.72% |
| FCF Yield | -166.63% |
Analyst Forecast
The average price target for Aethlon Medical is $13.25, which is 118.29% higher than the current price. The consensus rating is "Hold".
| Price Target | $13.25 |
| Price Target Difference | 118.29% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 4, 2026. It was a reverse split with a ratio of 1:5.
| Last Split Date | Aug 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |